GEN Exclusives

More »

GEN News Highlights

Back to Item »

Xoma and Servier’s mAb Fails to Reduce HbA1C Levels in Phase IIb Type 2 Diabetes Study

Xoma 052 does impact on CRP and HDL, which is promising for planned CVD and Behcet’s uveitis programs, firms claim.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »